ELISpot ＆ FluoroSpot アッセイ市場 : 2028年までの世界予測

Report Overview

The global ELISpot and FluoroSpot Assays Market is expected to reach USD 421 million by 2028 from USD 292 million in 2023, at a CAGR of 7.6% during the forecast period. Market is driven by factors such as Increasing use of ELISpot and FluoroSpot assays in oncology, growth in biotechnology and biopharmaceutical industries. On the other hand, availability of alternative detection technologies is expected to limit market growth to a certain extent in the coming years. 

“The Assay kits accounted for the largest market share in the ELISpot and FluoroSpot Assays product’ smarket, during the forecast period”
The ELISpot and FluoroSpot Assay Products market is segmented into Assay kits, Analyzers, and Ancillary Products. In 2022, kits accounted for a sizable market share because they offer advantages in terms of high specificity and sensitivity and better detection limits as compared to other assays such as ELISA as well as their wide applications in the field of research and diagnostics.

“Diagnostic application segment accounted for the largest market share”
Based on type of application, the ELISpot and FluoroSpot Assays market is segmented into Diagnostic and Research Application. The Diagnostic application segment accounted for the largest market share in 2022., while research application is expected to grow at the fastest rate in the years ahead, from 2023 to 2028 considering their practice in several research applications, such as vaccine development, clinical trials, and cancer research.

“APAC region accounted for the highest CAGR”
The global ELISpot and FluoroSpot Assays market is divided into four regions: North America, Asia-Pacific, Europe, and Rest of the World. According to the regional analysis, the Asia-Pacific region is likely to retain a significant market share in 2022 and the future. The Asia-Pacific market is being propelled by an increase in non-communicable (NCD), research funding on vaccines and changing disease profiles. North America, on the other hand, will experience significant growth in the coming years due to the presence of key players, the availability of technologically advanced ELISpot and FluoroSpot assay kits and analyzers.

“Europe is estimated to register the third highest CAGR during the forecast period.”
In this report, the ELISpot and FluoroSpot Assays market is segmented into four major regional segments: North America, Europe, Asia Pacific, Rest of the world. The market in Europe is projected to register the third highest growth rate during the forecast period. The growth in this market is due to Europe has a strong tradition of research and academic excellence, the rising incidence of chronic diseases, including autoimmune disorders and infectious diseases, government funding for research and healthcare in many European countries supports the development and adoption of advanced diagnostic technologies.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 – 32%, Tier 2 – 44%, and Tier 3 – 24%
• By Designation: C-level – 30%, D-level – 34%, and Others – 36%
• By Region: North America – 40%, Europe – 28%, Asia Pacific – 20%, and the Rest of the World – 12%
Lits of Companies Profiled in the Report:
• Oxford Immunotec USA, Inc. (Subsidiary of Revvity Inc.) (UK)
• Becton, Dickinson and Company (BD) (US)
• Cellular Technology Limited (CTL) (US)
• Mabtech (Sweden)
• Abcam plc. (UK)
• Bio-Techne (US)
• Merck KGaA (Germany)
• Autoimmun Diagnostika GmbH (Germany)
• U-CyTech (Netherland)
• Mikrogen Diagnostik (Germany)
• Medix Biochemica (Finland)
• Abnova Corporation (Taiwan)
• Anogen-Yes Biotech Laboratories Ltd. (Canada)
• Biorbyt Ltd (UK)
• BIOSYS Scientific Devices GmbH (Germany)
• Jackson ImmunoResearch Inc. (US)
• iST Scientific (UK)
• SERVA Electrophoresis GmbH (Germany)
• ACROBiosystems (US)
• NATIONAL ANALYTICAL CORPORATION (India)
• STEMCELL Technologies. (Canada)
• ZenBio, Inc (US)
• BOC Sciences (US)
• Tokyo Chemical Industry Co., Ltd. (TCI) (Japan)
• MP Biomedicals (California)

Research Coverage:
This report studies the ELISpot and FluoroSpot Assays market based on product, applications, End user, and region. The report also analyses factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total ELISpot and FluoroSpot Assays market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:
Market Drivers: Comprehensive information about driving factors of the markets. The report analyses the markets drivers across key geographic regions.
Market Penetration: Comprehensive information on ELISpot and FluoroSpot assay products offered by the top 25 players in the market. The report analyses the ELISpot and FluoroSpot Assays market by product, application, end user and region.
Market Development: Comprehensive information about lucrative emerging markets. The report analyses the markets for various securement devices across key geographic regions.
Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the ELISpot and FluoroSpot Assays market
Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the ELISpot and FluoroSpot Assays market
Market Position: It will upkeep stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies.

Table of Contents

1            INTRODUCTION            32

1.1         STUDY OBJECTIVES      32

1.2         MARKET DEFINITION   32

1.2.1      INCLUSIONS AND EXCLUSIONS OF STUDY         33

1.3         MARKET SCOPE             34

1.3.1      MARKET SEGMENTATION         34

1.3.2      REGIONAL SEGMENTATION     34

1.3.3      YEARS CONSIDERED     35

1.4         CURRENCY        35

1.5         LIMITATIONS   35

1.6         MARKET STAKEHOLDERS          36

1.7         SUMMARY OF CHANGES            36

1.8         RECESSION IMPACT      37

2            RESEARCH METHODOLOGY     38

2.1         RESEARCH DATA           38

FIGURE 1           RESEARCH DESIGN       38

2.1.1      SECONDARY DATA       39

2.1.1.1   Secondary sources             39

2.1.2      PRIMARY DATA 40

FIGURE 2           PRIMARY SOURCES       40

2.1.2.1   Key data from primary sources         41

2.1.2.2   Key industry insights          42

2.1.2.3   Breakdown of primary interviews     43

FIGURE 3           BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND  DEMAND-SIDE PARTICIPANTS 43

FIGURE 4           BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,  AND REGION  43

2.2         MARKET SIZE ESTIMATION       44

FIGURE 5           REVENUE SHARE ANALYSIS ILLUSTRATION: OXFORD IMMUNOTEC USA, INC. (SUBSIDIARY OF REVVITY, INC.) (UK)   44

FIGURE 6           MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH  45

2.2.1      GROWTH FORECAST    45

FIGURE 7           CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS   46

FIGURE 8           TOP-DOWN APPROACH             46

2.3         MARKET BREAKDOWN AND DATA TRIANGULATION    48

FIGURE 9           DATA TRIANGULATION METHODOLOGY         48

2.4         MARKET SHARE ANALYSIS         49

2.5         STUDY ASSUMPTIONS  49

2.6         RISK ASSESSMENT         49

TABLE 1             RISK ASSESSMENT         49

2.7         RECESSION IMPACT ANALYSIS 50

3            EXECUTIVE SUMMARY 51

FIGURE 10         ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)     51

FIGURE 11         ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION,  2023 VS. 2028 (USD MILLION)   52

FIGURE 12         ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER,  2023 VS. 2028 (USD MILLION)     52

FIGURE 13         ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY REGION,  2023 VS. 2028 (USD MILLION)     53

4            PREMIUM INSIGHTS      54

4.1         ELISPOT AND FLUOROSPOT ASSAYS MARKET OVERVIEW          54

FIGURE 14         RISING INCIDENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET       54

4.2         ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY TECHNIQUE, 2023–2028          54

FIGURE 15         ELISPOT ASSAY KITS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD       54

4.3         NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET,  BY PRODUCT AND COUNTRY (2022)           55

FIGURE 16         ASSAY KITS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN ELISPOT AND FLUOROSPOT ASSAYS MARKET IN 2022          55

4.4         ELISPOT AND FLUOROSPOT ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES           56

FIGURE 17         ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD     56

5            MARKET OVERVIEW     57

5.1         INTRODUCTION            57

5.2         MARKET DYNAMICS     57

FIGURE 18         ELISPOT AND FLUOROSPOT ASSAYS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES       57

5.2.1      DRIVERS            58

5.2.1.1   Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis            58

FIGURE 19         INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION)        58

TABLE 2             GLOBAL INCIDENCE OF INFECTIOUS DISEASES             59

5.2.1.2   Increasing vaccine development to address challenges of antimicrobial resistance              59

5.2.1.3   Increasing use of ELISpot and FluoroSpot assays in oncology    61

TABLE 3             INCIDENCE OF CANCER IN MEN, 2020   61

TABLE 4             INCIDENCE OF CANCER IN WOMEN, 2020           61

5.2.1.4   ELISpot assays as diagnostic tool in drug  hypersensitivity reaction        62

TABLE 5             EXAMPLES OF ELISPOT ASSAYS IN DRUG HYPERSENSITIVITY REACTIONS      63

5.2.1.5   Growth in biotechnology and biopharmaceutical industries        63

5.2.2      RESTRAINTS     64

5.2.2.1   Stringent requirements for approval of ELISpot and FluoroSpot assay instruments and consumables 64

5.2.2.2   High cost of assay kits and analyzers 65

5.2.3      OPPORTUNITIES           65

5.2.3.1   Use of FluoroSpot assays for multiple-analyte detection  in single well   65

5.2.3.2   Emerging economies         66

FIGURE 20        HEALTHCARE EXPENDITURE PER CAPITA IN BRIC COUNTRIES, 2012–2020          67

5.2.4      CHALLENGES   67

5.2.4.1   Availability of alternative detection technologies          67

5.2.4.2   Dearth of skilled professionals         67

5.3         VALUE CHAIN ANALYSIS            68

FIGURE 21         VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES      68

5.4         SUPPLY CHAIN ANALYSIS          69

FIGURE 22         DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES          69

5.5         TECHNOLOGY ANALYSIS           70

5.6         PORTER’S FIVE FORCES ANALYSIS         70

5.6.1      THREAT OF NEW ENTRANTS    71

5.6.2      INTENSITY OF COMPETITIVE RIVALRY 71

5.6.3      BARGAINING POWER OF BUYERS           71

5.6.4      BARGAINING POWER OF SUPPLIERS     71

5.6.5      THREAT OF SUBSTITUTES         71

5.7         KEY STAKEHOLDERS AND BUYING CRITERIA    72

5.7.1      KEY STAKEHOLDERS IN BUYING PROCESS         72

FIGURE 23         INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS       72

TABLE 6             INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS (%) 72

5.7.2      BUYING CRITERIA         72

FIGURE 24         KEY BUYING CRITERIA FOR END USERS              72

TABLE 7             KEY BUYING CRITERIA FOR END USERS              73

5.8         REGULATORY LANDSCAPE       73

TABLE 8             REGULATORY AUTHORITIES GOVERNING ELISPOT AND FLUOROSPOT ASSAYS MARKET 73

5.8.1      US         74

TABLE 9             US: CLASSIFICATION OF ELISPOT AND FLUOROSPOT ASSAY PRODUCTS       74

FIGURE 25         US: REGULATORY PROCESS FOR IVD DEVICES  75

5.8.2      CANADA            76

FIGURE 26         CANADA: REGULATORY PROCESS FOR IVD DEVICES     76

5.8.3      EUROPE             76

TABLE 10           EUROPE: CLASSIFICATION OF IVD DEVICES      77

5.8.4      JAPAN  78

FIGURE 27         JAPAN: REGULATORY PROCESS FOR IVD DEVICES         78

TABLE 11           JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS           78

5.8.5      CHINA  79

TABLE 12           CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS           79

5.8.6      INDIA   79

FIGURE 28         INDIA: REGULATORY PROCESS FOR IVD DEVICES          80

5.8.7      RUSSIA 80

TABLE 13           RUSSIA: CLASSIFICATION OF IVD DEVICES        80

5.8.8      SAUDI ARABIA  80

TABLE 14           SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS          81

5.8.9      MEXICO             81

FIGURE 29         MEXICO: REGULATORY PROCESS FOR IVD DEVICES      81

TABLE 15           MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS           82

5.8.10    BRAZIL 83

FIGURE 30         BRAZIL: REGULATORY PROCESS FOR IVD DEVICES       83

5.8.11    SOUTH KOREA 83

TABLE 16           SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS          83

5.8.12    MIDDLE EAST  84

5.8.13    AFRICA 84

5.9         KEY CONFERENCES AND EVENTS          84

TABLE 17           LIST OF CONFERENCES AND EVENTS, 2023–2025            84

5.10       PATENT ANALYSIS        85

FIGURE 31         PATENT ANALYSIS FOR ELISPOT AND FLUOROSPOT ASSAYS              85

5.11       PRICING ANALYSIS        86

TABLE 18           ELISPOT AND FLUOROSPOT ASSAYS MARKET: PRICE RANGE FOR ELISPOT AND FLUOROSPOT ASSAY PRODUCTS     86

TABLE 19           AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY KEY PLAYERS (2022) 86

5.12       TRADE ANALYSIS          86

5.12.1    TRADE ANALYSIS FOR ELISPOT AND FLUOROSPOT ASSAYS      86

TABLE 20           IMPORT DATA FOR HS CODE 382200, BY COUNTRY, 2017–2022 (USD MILLION) 87

TABLE 21           EXPORT DATA FOR HS CODE 382200, BY COUNTRY, 2017–2022 (USD MILLION) 87

5.13       ECOSYSTEM ANALYSIS 88

5.13.1    ROLE IN ECOSYSTEM    88

FIGURE 32         KEY PLAYERS OPERATING IN ELISPOT AND FLUOROSPOT ASSAYS MARKET            89

5.14       TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS     89

6            ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT    90

6.1         INTRODUCTION            91

TABLE 22           ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)          91

6.2         ASSAY KITS       91

TABLE 23           ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY REGION,  2020–2028 (USD MILLION)          92

TABLE 24           NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY COUNTRY,  2020–2028 (USD MILLION)      92

TABLE 25           EUROPE: ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY COUNTRY,  2020–2028 (USD MILLION) 92

TABLE 26           ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY COUNTRY,  2020–2028 (USD MILLION)      93

6.2.1      ASSAY KITS MARKET, BY TECHNIQUE   93

TABLE 27           ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY TECHNIQUE,  2020–2028 (USD MILLION)           93

6.2.1.1   ELISpot assay kits 93

6.2.1.1.1 Need for highly sensitive immune monitoring requirements in clinical trials to drive market        93

TABLE 28           ELISPOT ASSAY KITS MARKET, BY REGION, 2020–2028 (USD MILLION)          94

TABLE 29           NORTH AMERICA: ELISPOT ASSAY KITS MARKET, BY COUNTRY,  2020–2028 (USD MILLION) 94

TABLE 30           EUROPE: ELISPOT ASSAY KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)     95

TABLE 31           ASIA PACIFIC: ELISPOT ASSAY KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)          95

6.2.1.2   FluoroSpot assay kits         95

6.2.1.2.1 Increasing demand for multiple analyte detection and technological advancements to support market growth   95

TABLE 32           FLUOROSPOT ASSAY KITS MARKET, BY REGION, 2020–2028 (USD MILLION) 96

TABLE 33           NORTH AMERICA: FLUOROSPOT ASSAY KITS MARKET, BY COUNTRY,  2020–2028 (USD MILLION) 96

TABLE 34           EUROPE: FLUOROSPOT ASSAY KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)          97

TABLE 35           ASIA PACIFIC: FLUOROSPOT ASSAY KITS MARKET, BY COUNTRY,  2020–2028 (USD MILLION) 97

6.2.2      ASSAY KITS MARKET, BY UTILITY           97

TABLE 36           ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY UTILITY, 2020–2028 (USD MILLION)          97

6.2.2.1   Diagnostic kits     98

6.2.2.1.1 Need for early diagnosis of infections to drive market  98

TABLE 37           CANCER CASES, BY TYPE, 2020  98

TABLE 38           DIAGNOSTIC KITS MARKET, BY REGION, 2020–2028 (USD MILLION)          98

TABLE 39           NORTH AMERICA: DIAGNOSTIC KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)          99

TABLE 40           EUROPE: DIAGNOSTIC KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION) 99

TABLE 41           ASIA PACIFIC: DIAGNOSTIC KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)     99

6.2.2.2   Research kits        100

6.2.2.2.1 Increasing investments in vaccine research, clinical trials, and cancer research to drive market        100

TABLE 42           RESEARCH KITS MARKET, BY REGION, 2020–2028 (USD MILLION)          100

TABLE 43           NORTH AMERICA: RESEARCH KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)          100

TABLE 44           EUROPE: RESEARCH KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION) 101

TABLE 45           ASIA PACIFIC: RESEARCH KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)     101

6.2.3      ASSAY KITS MARKET, BY ANALYTE        101

TABLE 46           ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY ANALYTE,  2020–2028 (USD MILLION)  101

6.2.3.1   T-cell-based kits  102

6.2.3.1.1 Low concentrations of infection-released analytes necessitate use of T-cell-based kits         102

TABLE 47           T-CELL-BASED KITS MARKET, BY REGION, 2020–2028 (USD MILLION)          102

TABLE 48          NORTH AMERICA: T-CELL-BASED KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)          102

TABLE 49           EUROPE: T-CELL-BASED KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)     103

TABLE 50           ASIA PACIFIC: T-CELL-BASED KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)          103

6.2.3.2   B-cell-based kits  103

6.2.3.2.1 Detection of B-cell-based antibodies useful to study cell response post-infection/vaccination         103

TABLE 51           B-CELL-BASED KITS MARKET, BY REGION, 2020–2028 (USD MILLION)          104

TABLE 52          NORTH AMERICA: B-CELL-BASED KITS MARKET, BY COUNTRY,  2020–2028 (USD MILLION)          104

TABLE 53           EUROPE: B-CELL-BASED KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)     104

TABLE 54           ASIA PACIFIC: B-CELL-BASED KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)          105

6.2.3.3   Other analyte kits 105

TABLE 55           OTHER ANALYTE KITS MARKET, BY REGION, 2020–2028 (USD MILLION)          105

TABLE 56           NORTH AMERICA: OTHER ANALYTE KITS MARKET, BY COUNTRY,  2020–2028 (USD MILLION) 106

TABLE 57           EUROPE: OTHER ANALYTE KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)     106

TABLE 58           ASIA PACIFIC: OTHER ANALYTE KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)          106

6.3         ANALYZERS      107

6.3.1      ADOPTION OF ASSAY KITS TO DRIVE USE OF ANALYZERS         107

TABLE 59          ELISPOT AND FLUOROSPOT ANALYZERS MARKET, BY REGION,  2020–2028 (USD MILLION)          107

TABLE 60           NORTH AMERICA: ELISPOT AND FLUOROSPOT ANALYZERS MARKET, BY COUNTRY,  2020–2028 (USD MILLION)      107

TABLE 61           EUROPE: ELISPOT AND FLUOROSPOT ANALYZERS MARKET, BY COUNTRY,  2020–2028 (USD MILLION)         108

TABLE 62           ASIA PACIFIC: ELISPOT AND FLUOROSPOT ANALYZERS MARKET, BY COUNTRY,  2020–2028 (USD MILLION)      108

6.4         ANCILLARY PRODUCTS             108

6.4.1      REPEATED USAGE OF ANCILLARY PRODUCTS INTEGRAL TO RELIABILITY AND SUCCESS OF ELISPOT AND FLUOROSPOT ASSAYS     108

TABLE 63           ELISPOT AND FLUOROSPOT ANCILLARY PRODUCTS MARKET, BY REGION,  2020–2028 (USD MILLION)             109

TABLE 64           NORTH AMERICA: ELISPOT AND FLUOROSPOT ANCILLARY PRODUCTS MARKET,  BY COUNTRY, 2020–2028 (USD MILLION)             109

TABLE 65           EUROPE: ELISPOT AND FLUOROSPOT ANCILLARY PRODUCTS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)         109

TABLE 66           ASIA PACIFIC: ELISPOT AND FLUOROSPOT ANCILLARY PRODUCTS MARKET, BY COUNTRY, 2020–2028 (USD MILLION) 110

7            ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION              111

7.1         INTRODUCTION            112

TABLE 67           ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION,  2020–2028 (USD MILLION)        112

7.2         DIAGNOSTIC APPLICATIONS    112

TABLE 68           ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR DIAGNOSTIC APPLICATIONS,  BY TYPE, 2020–2028 (USD MILLION)       112

TABLE 69           ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR DIAGNOSTIC APPLICATIONS,  BY REGION, 2020–2028 (USD MILLION)  113

TABLE 70           NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2028 (USD MILLION)          113

TABLE 71           EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2028 (USD MILLION) 113

TABLE 72           ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2028 (USD MILLION)              114

7.2.1      INFECTIOUS DISEASES 114

7.2.1.1   Rising prevalence of infectious diseases to drive market             114

TABLE 73           ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR INFECTIOUS DISEASES, BY REGION,  2020–2028 (USD MILLION)             115

TABLE 74           NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2028 (USD MILLION)              115

TABLE 75           EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR INFECTIOUS DISEASES,  BY COUNTRY, 2020–2028 (USD MILLION)         115

TABLE 76           ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2028 (USD MILLION)   116

7.2.2      TRANSPLANTS 116

7.2.2.1   Growing incidence of infections caused during transplant procedures to drive demand 116

FIGURE 33         PATIENTS ON WAITING LIST FOR ORGAN TRANSPLANTS, 2023              117

FIGURE 34         NUMBER OF TRANSPLANTS PERFORMED IN 2023           117

TABLE 77           ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR TRANSPLANTS, BY REGION,  2020–2028 (USD MILLION)             118

TABLE 78           NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR TRANSPLANTS,  BY COUNTRY, 2020–2028 (USD MILLION)              118

TABLE 79           EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR TRANSPLANTS, BY COUNTRY, 2020–2028 (USD MILLION)            118

TABLE 80           ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR TRANSPLANTS,  BY COUNTRY, 2020–2028 (USD MILLION) 119

7.3         RESEARCH APPLICATIONS        119

TABLE 81           ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY TYPE,  2020–2028 (USD MILLION)   119

TABLE 82           ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY REGION,  2020–2028 (USD MILLION)            120

TABLE 83           NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2028 (USD MILLION)          120

TABLE 84           EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2028 (USD MILLION)     120

TABLE 85           ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH APPLICATIONS,  BY COUNTRY, 2020–2028 (USD MILLION)        121

7.3.1      VACCINE DEVELOPMENT          121

7.3.1.1   Largest and fastest-growing segment of market            121

TABLE 86           ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR VACCINE DEVELOPMENT, BY REGION,  2020–2028 (USD MILLION)           122

TABLE 87           NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2020–2028 (USD MILLION)          122

TABLE 88           EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR VACCINE DEVELOPMENT,  BY COUNTRY, 2020–2028 (USD MILLION)    122

TABLE 89           ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2020–2028 (USD MILLION)              123

7.3.2      CLINICAL TRIALS          123

7.3.2.1   Growing number of clinical trials to drive demand       123

FIGURE 35         NUMBER OF CLINICAL TRIALS, BY REGION, 2010–2021  123

FIGURE 36         NUMBER OF REGISTERED CLINICAL STUDIES, 2023       124

TABLE 90           ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CLINICAL TRIALS, BY REGION,  2020–2028 (USD MILLION)             124

TABLE 91           NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CLINICAL TRIALS,  BY COUNTRY, 2020–2028 (USD MILLION)              124

TABLE 92           EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CLINICAL TRIALS,  BY COUNTRY, 2020–2028 (USD MILLION)    125

TABLE 93           ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CLINICAL TRIALS,  BY COUNTRY, 2020–2028 (USD MILLION)          125

7.3.3      CANCER RESEARCH      125

7.3.3.1   Rising prevalence of cancer to support market growth  125

TABLE 94           ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CANCER RESEARCH, BY REGION,  2020–2028 (USD MILLION)      126

TABLE 95           NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CANCER RESEARCH, BY COUNTRY, 2020–2028 (USD MILLION)              127

TABLE 96           EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CANCER RESEARCH,  BY COUNTRY, 2020–2028 (USD MILLION) 127

TABLE 97           ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CANCER RESEARCH,  BY COUNTRY, 2020–2028 (USD MILLION)      127

8            ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER     128

8.1         INTRODUCTION            129

TABLE 98           ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)          129

8.2         HOSPITAL AND CLINICAL LABORATORIES        129

8.2.1      IMPROVING HEALTHCARE INFRASTRUCTURE IN DEVELOPING COUNTRIES TO DRIVE MARKET             129

TABLE 99           ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR HOSPITAL AND CLINICAL LABORATORIES, BY REGION, 2020–2028 (USD MILLION) 130

TABLE 100         NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR HOSPITAL AND CLINICAL LABORATORIES, BY COUNTRY, 2020–2028 (USD MILLION)     130

TABLE 101         EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR HOSPITAL AND CLINICAL LABORATORIES, BY COUNTRY, 2020–2028 (USD MILLION)          131

TABLE 102         ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR HOSPITAL AND CLINICAL LABORATORIES, BY COUNTRY, 2020–2028 (USD MILLION)          131

8.3         RESEARCH INSTITUTES             131

8.3.1      FASTEST-GROWING END USER OF ELISPOT AND  FLUOROSPOT ASSAYS 131

TABLE 103         GRANTS, BY CANCER TYPE, 2023            132

TABLE 104         ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH INSTITUTES, BY REGION,  2020–2028 (USD MILLION)   133

TABLE 105         NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2020–2028 (USD MILLION)              133

TABLE 106         EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH INSTITUTES,  BY COUNTRY, 2020–2028 (USD MILLION)        133

TABLE 107         ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2020–2028 (USD MILLION)  134

8.4         BIOPHARMACEUTICAL COMPANIES AND CONTRACT  RESEARCH ORGANIZATIONS          134

8.4.1      GROWTH IN BIOTECHNOLOGY INDUSTRY TO PROPEL GROWTH              134

TABLE 108         ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY REGION, 2020–2028 (USD MILLION)          135

TABLE 109         NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2020–2028 (USD MILLION)          135

TABLE 110         EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2020–2028 (USD MILLION)          135

TABLE 111         ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2020–2028 (USD MILLION) 136

9            ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY REGION        137

9.1         INTRODUCTION            138

TABLE 112         ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY REGION, 2020–2028 (USD MILLION)          138

9.2         NORTH AMERICA          138

FIGURE 37         NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET SNAPSHOT     139

TABLE 113         NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY COUNTRY,  2020–2028 (USD MILLION)      139

TABLE 114         NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT,  2020–2028 (USD MILLION)      140

TABLE 115         NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION,  2020–2028 (USD MILLION)             140

TABLE 116         NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER,  2020–2028 (USD MILLION)      140

9.2.1      NORTH AMERICA: RECESSION IMPACT 141

9.2.2      US         141

9.2.2.1   Rising prevalence of chronic diseases to drive market   141

TABLE 117         US: KEY MACROINDICATORS    142

TABLE 118         US: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT,  2020–2028 (USD MILLION) 142

TABLE 119         US: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION,  2020–2028 (USD MILLION)        142

TABLE 120         US: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER,  2020–2028 (USD MILLION)          143

9.2.3      CANADA            143

9.2.3.1   Rising healthcare expenditure to drive adoption of ELISpot and FluoroSpot assays              143

TABLE 121         CANADA: KEY MACROINDICATORS       144

TABLE 122         CANADA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT,  2020–2028 (USD MILLION) 144

TABLE 123         CANADA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION,  2020–2028 (USD MILLION)        145

TABLE 124         CANADA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER,  2020–2028 (USD MILLION) 145

9.3         EUROPE             145

TABLE 125         EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY   146

9.3.1      EUROPE: RECESSION IMPACT   146

TABLE 126         EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY COUNTRY,  2020–2028 (USD MILLION) 147

TABLE 127         EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT,  2020–2028 (USD MILLION) 147

TABLE 128         EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION,  2020–2028 (USD MILLION)        147

TABLE 129         EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER,  2020–2028 (USD MILLION) 148

9.3.2      GERMANY         148

9.3.2.1   Fastest-growing country in European ELISpot and FluoroSpot assays market              148

TABLE 130         GERMANY: KEY MACROINDICATORS    149

TABLE 131         GERMANY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT,  2020–2028 (USD MILLION) 149

TABLE 132         GERMANY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION,  2020–2028 (USD MILLION)        149

TABLE 133         GERMANY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER,  2020–2028 (USD MILLION) 150

9.3.3      UK         150

9.3.3.1   Rising prevalence of NCDs to drive market    150

TABLE 134         UK: KEY MACROINDICATORS   151

TABLE 135         UK: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT,  2020–2028 (USD MILLION) 151

TABLE 136         UK: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION,  2020–2028 (USD MILLION)        151

TABLE 137         UK: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER,  2020–2028 (USD MILLION)          152

9.3.4      FRANCE             152

9.3.4.1   Need for early disease diagnosis to support market growth         152

TABLE 138         FRANCE: KEY MACROINDICATORS        153

TABLE 139         FRANCE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT,  2020–2028 (USD MILLION) 153

TABLE 140         FRANCE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION,  2020–2028 (USD MILLION)        153

TABLE 141         FRANCE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER,  2020–2028 (USD MILLION) 154

9.3.5      ITALY   154

9.3.5.1   Increasing incidence of cancer to propel market           154

TABLE 142         ITALY: KEY MACROINDICATORS            155

TABLE 143         ITALY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT,  2020–2028 (USD MILLION) 155

TABLE 144         ITALY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION,  2020–2028 (USD MILLION)        155

TABLE 145         ITALY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER,  2020–2028 (USD MILLION)          156

9.3.6      SPAIN   156

9.3.6.1   High incidence of chronic diseases to drive market      156

TABLE 146         SPAIN: KEY MACROINDICATORS            157

TABLE 147         SPAIN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT,  2020–2028 (USD MILLION) 157

TABLE 148         SPAIN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION,  2020–2028 (USD MILLION)        157

TABLE 149         SPAIN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER,  2020–2028 (USD MILLION)          158

9.3.7      REST OF EUROPE           158

TABLE 150         REST OF EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT,  2020–2028 (USD MILLION)      159

TABLE 151         REST OF EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION,  2020–2028 (USD MILLION)             159

TABLE 152         REST OF EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER,  2020–2028 (USD MILLION)      160

9.4         ASIA PACIFIC    160

9.4.1      ASIA PACIFIC: RECESSION IMPACT        160

FIGURE 38         ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET SNAPSHOT        161

TABLE 153         ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY COUNTRY,  2020–2028 (USD MILLION)         161

TABLE 154         ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT,  2020–2028 (USD MILLION)         162

TABLE 155         ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION,  2020–2028 (USD MILLION)   162

TABLE 156         ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER,  2020–2028 (USD MILLION)         162

9.4.2      CHINA  163

9.4.2.1   Rising focus on vaccine development and cancer research to drive market              163

TABLE 157         CHINA: KEY MACROINDICATORS           164

TABLE 158         CHINA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT,  2020–2028 (USD MILLION) 164

TABLE 159         CHINA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION,  2020–2028 (USD MILLION)        164

TABLE 160         CHINA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER,  2020–2028 (USD MILLION)          165

9.4.3      JAPAN  165

9.4.3.1   Increased focus on vaccine research to support market growth   165

TABLE 161         JAPAN: KEY MACROINDICATORS           166

TABLE 162         JAPAN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT,  2020–2028 (USD MILLION) 166

TABLE 163         JAPAN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION,  2020–2028 (USD MILLION)        166

TABLE 164         JAPAN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER,  2020–2028 (USD MILLION)          167

9.4.4      INDIA   167

9.4.4.1   Increasing focus on cancer research and therapy to drive market              167

TABLE 165         INDIA: KEY MACROINDICATORS            168

TABLE 166         INDIA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT,  2020–2028 (USD MILLION) 168

TABLE 167         INDIA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION,  2020–2028 (USD MILLION)        168

TABLE 168         INDIA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER,  2020–2028 (USD MILLION)          169

9.4.5      REST OF ASIA PACIFIC  169

TABLE 169         REST OF ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)        170

TABLE 170         REST OF ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION,  2020–2028 (USD MILLION)             170

TABLE 171         REST OF ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER,  2020–2028 (USD MILLION)      170

9.5         REST OF THE WORLD   171

TABLE 172         REST OF THE WORLD: POPULATION AGED 65 AND ABOVE, 2022      171

9.5.1      REST OF THE WORLD: RECESSION IMPACT       172

TABLE 173         REST OF THE WORLD: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT,  2020–2028 (USD MILLION)      172

TABLE 174         REST OF THE WORLD: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)  172

TABLE 175         REST OF THE WORLD: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER,  2020–2028 (USD MILLION)      173

10          COMPETITIVE LANDSCAPE       174

10.1       OVERVIEW        174

10.2       STRATEGIES ADOPTED BY KEY PLAYERS           174

TABLE 176         OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ELISPOT AND FLUOROSPOT ASSAYS MARKET  174

10.3       MARKET SHARE ANALYSIS         175

TABLE 177         ELISPOT AND FLUOROSPOT ASSAYS MARKET: DEGREE OF COMPETITION 175

10.4       REVENUE SHARE ANALYSIS       176

FIGURE 39         REVENUE ANALYSIS OF KEY PUBLIC PLAYERS IN ELISPOT AND  FLUOROSPOT ASSAYS MARKET 176

FIGURE 40         ELISPOT AND FLUOROSPOT ASSAYS: MARKET RANKING ANALYSIS, 2022 176

10.5       COMPANY EVALUATION MATRIX          178

10.5.1    STARS  178

10.5.2    EMERGING LEADERS    178

10.5.3    PERVASIVE PLAYERS     178

10.5.4    PARTICIPANTS 178

FIGURE 41         ELISPOT AND FLUOROSPOT ASSAYS MARKET: COMPANY EVALUATION  MATRIX, 2022    179

10.6       SME/STARTUP EVALUATION MATRIX   180

10.6.1    PROGRESSIVE COMPANIES       180

10.6.2    RESPONSIVE COMPANIES          180

10.6.3    DYNAMIC COMPANIES 180

10.6.4    STARTING BLOCKS       180

FIGURE 42         ELISPOT AND FLUOROSPOT ASSAYS MARKET: SME/STARTUP EVALUATION MATRIX, 2022      181

10.7       COMPETITIVE BENCHMARKING            182

TABLE 178         ELISPOT AND FLUOROSPOT ASSAYS MARKET: DETAILED LIST OF KEY STARTUPS/SMES           182

10.8       COMPANY FOOTPRINT 182

TABLE 179         COMPANY FOOTPRINT 182

TABLE 180         PRODUCT FOOTPRINT 183

TABLE 181         REGIONAL FOOTPRINT             184

10.9       COMPETITIVE SCENARIO          186

10.9.1    PRODUCT LAUNCHES  186

TABLE 182         KEY PRODUCT LAUNCHES, JANUARY 2020–OCTOBER 2023              186

10.9.2    DEALS  186

TABLE 183         KEY DEALS, JANUARY 2020–OCTOBER 2023        186

10.9.3    OTHER DEVELOPMENTS           187

TABLE 184         OTHER KEY DEVELOPMENTS, JANUARY 2020–OCTOBER 2023              187

11          COMPANY PROFILES    188

(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *

11.1       KEY PLAYERS   188

11.1.1    OXFORD IMMUNOTEC USA, INC. (SUBSIDIARY OF REVVITY, INC.)              188

TABLE 185         OXFORD IMMUNOTEC USA, INC. (SUBSIDIARY OF REVVITY, INC.): BUSINESS OVERVIEW      188

FIGURE 43         REVVITY, INC.: COMPANY SNAPSHOT (2023)     189

11.1.2    BECTON, DICKINSON AND COMPANY  192

TABLE 186         BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW              192

FIGURE 44         BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)   193

11.1.3    BIO-TECHNE    196

TABLE 187         BIO-TECHNE: BUSINESS OVERVIEW      196

FIGURE 45         BIO-TECHNE: COMPANY SNAPSHOT (2023)       197

11.1.4    CELLULAR TECHNOLOGY LIMITED      200

TABLE 188         CELLULAR TECHNOLOGY LIMITED: BUSINESS OVERVIEW              200

11.1.5    MABTECH         203

TABLE 189         MABTECH: BUSINESS OVERVIEW           203

11.1.6    ABCAM PLC      205

TABLE 190         ABCAM PLC: BUSINESS OVERVIEW        205

FIGURE 46         ABCAM PLC: COMPANY SNAPSHOT (2022)         206

11.1.7    MERCK KGAA   209

TABLE 191         MERCK KGAA: BUSINESS OVERVIEW     209

FIGURE 47         MERCK KGAA: COMPANY SNAPSHOT (2022)      210

11.1.8    AUTOIMMUN DIAGNOSTIKA GMBH      212

TABLE 192         AUTOIMMUN DIAGNOSTIKA GMBH: BUSINESS OVERVIEW              212

11.1.9    U-CYTECH        214

TABLE 193         U-CYTECH: BUSINESS OVERVIEW          214

11.1.10  MIKROGEN DIAGNOSTIK           216

TABLE 194         MIKROGEN DIAGNOSTIK: BUSINESS OVERVIEW             216

11.1.11  MEDIX BIOCHEMICA     217

TABLE 195         MEDIX BIOCHEMICA: BUSINESS OVERVIEW       217

11.1.12  ABNOVA CORPORATION           219

TABLE 196         ABNOVA CORPORATION: BUSINESS OVERVIEW             219

11.1.13  ANOGEN-YES BIOTECH LABORATORIES LTD.   220

TABLE 197         ANOGEN-YES BIOTECH LABORATORIES LTD.: BUSINESS OVERVIEW        220

11.1.14  BIORBYT LTD.  221

TABLE 198         BIORBYT LTD.: BUSINESS OVERVIEW    221

11.1.15  BIOSYS SCIENTIFIC DEVICES GMBH      223

TABLE 199         BIOSYS SCIENTIFIC DEVICES GMBH: BUSINESS OVERVIEW              223

11.2       OTHER PLAYERS           224

11.2.1    JACKSON IMMUNORESEARCH INC.        224

TABLE 200         JACKSON IMMUNORESEARCH INC.: BUSINESS OVERVIEW              224

11.2.2    IST SCIENTIFIC 225

TABLE 201         IST SCIENTIFIC: BUSINESS OVERVIEW  225

11.2.3    SERVA ELECTROPHORESIS GMBH         226

TABLE 202         SERVA ELECTROPHORESIS GMBH: BUSINESS OVERVIEW              226

11.2.4    ACROBIOSYSTEMS        227

TABLE 203         ACROBIOSYSTEMS: BUSINESS OVERVIEW          227

11.2.5    NATIONAL ANALYTICAL CORPORATION           228

TABLE 204         NATIONAL ANALYTICAL CORPORATION: BUSINESS OVERVIEW        228

11.2.6    STEMCELL TECHNOLOGIES      229

TABLE 205         STEMCELL TECHNOLOGIES: BUSINESS OVERVIEW        229

11.2.7    ZENBIO, INC.     230

TABLE 206         ZENBIO, INC.: BUSINESS OVERVIEW      230

11.2.8    BOC SCIENCES 231

TABLE 207         BOC SCIENCES: BUSINESS OVERVIEW   231

11.2.9    TOKYO CHEMICAL INDUSTRY CO., LTD.            232

TABLE 208         TOKYO CHEMICAL INDUSTRY CO., LTD.: BUSINESS OVERVIEW              232

11.2.10  MP BIOMEDICALS         233

TABLE 209         MP BIOMEDICALS: BUSINESS OVERVIEW           233

*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.

12          APPENDIX         234

12.1       INSIGHTS FROM INDUSTRY EXPERTS   234

12.2       DISCUSSION GUIDE      235

12.3       KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL             239

12.4       CUSTOMIZATION OPTIONS      241

12.5       RELATED REPORTS       241

12.6       AUTHOR DETAILS         242